etidronate has been researched along with Arthritis, Degenerative in 18 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Osteoarthritis was surgically induced on one knee of 32 New Zealand White rabbits using the contralateral as healthy controls." | 5.40 | Effects of glucosamine and risedronate alone or in combination in an experimental rabbit model of osteoarthritis. ( Caeiro, JR; González-Cantalapiedra, A; Guede, D; López-Peña, M; Muñoz, F; Permuy, M, 2014) |
| "Cohort study in a tertiary care university affiliated hospital in corticosteroid treated patients, with polymyalgia rheumatica, asthma, systemic lupus erythematosus, rheumatoid arthritis, or temporal arteritis, examining the effects of ICT etidronate." | 5.07 | Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. ( Adachi, J; Bensen, WG; Bianchi, F; Cividino, A; Craig, GL; Cranney, A; Goldsmith, CH; Kaminska, E; Papaioannou, A; Sebaldt, RJ, 1994) |
| " The patients received an oral dosage of about 20 mg/kg body weight the first 2 months and about 5 mg/kg from month 3-6." | 2.66 | [Therapy of psoriatic osteoarthropathy with EHDP]. ( Altmeyer, P; Holzmann, H; Hör, G; Maul, FD; Thiers, G, 1985) |
| "Osteoarthritis was surgically induced on one knee of 32 New Zealand White rabbits using the contralateral as healthy controls." | 1.40 | Effects of glucosamine and risedronate alone or in combination in an experimental rabbit model of osteoarthritis. ( Caeiro, JR; González-Cantalapiedra, A; Guede, D; López-Peña, M; Muñoz, F; Permuy, M, 2014) |
| " In two groups, anterior cruciate ligament transection was performed and half were left untreated, and the other half dosed with risedronate (0." | 1.35 | Preservation of periarticular cancellous morphology and mechanical stiffness in post-traumatic experimental osteoarthritis by antiresorptive therapy. ( Boyd, SK; Doschak, MR; MacNeil, JA; Zernicke, RF, 2008) |
| " We surgically transected the anterior cruciate ligament (ACLX) in two groups of rabbits; the first group was dosed with BP (risedronate, 0." | 1.32 | Antiresorptive therapy conserves some periarticular bone and ligament mechanical properties after anterior cruciate ligament disruption in the rabbit knee. ( Bray, RC; Doschak, MR; Hanley, DA; Wohl, GR; Zernicke, RF, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (44.44) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thomsen, JS | 1 |
| Straarup, TS | 1 |
| Danielsen, CC | 1 |
| Oxlund, H | 1 |
| Brüel, A | 1 |
| Permuy, M | 1 |
| Guede, D | 1 |
| López-Peña, M | 1 |
| Muñoz, F | 1 |
| González-Cantalapiedra, A | 1 |
| Caeiro, JR | 1 |
| Bruyère, O | 1 |
| Burlet, N | 1 |
| Delmas, PD | 1 |
| Rizzoli, R | 1 |
| Cooper, C | 1 |
| Reginster, JY | 1 |
| Yemisci, OU | 1 |
| Yalbuzdag, SA | 1 |
| Karatas, M | 1 |
| Doschak, MR | 2 |
| Wohl, GR | 1 |
| Hanley, DA | 1 |
| Bray, RC | 1 |
| Zernicke, RF | 2 |
| Felson, DT | 1 |
| Kim, YJ | 1 |
| MacNeil, JA | 1 |
| Boyd, SK | 1 |
| Kawasaki, T | 1 |
| Kurosawa, H | 1 |
| Ikeda, H | 1 |
| Kim, SG | 1 |
| Osawa, A | 1 |
| Takazawa, Y | 1 |
| Kubota, M | 1 |
| Ishijima, M | 1 |
| Halverson, PB | 2 |
| Cheung, HS | 1 |
| McCarty, DJ | 2 |
| Adachi, J | 1 |
| Cranney, A | 1 |
| Goldsmith, CH | 1 |
| Bensen, WG | 1 |
| Bianchi, F | 1 |
| Cividino, A | 1 |
| Craig, GL | 1 |
| Kaminska, E | 1 |
| Sebaldt, RJ | 1 |
| Papaioannou, A | 1 |
| Doyle, DV | 1 |
| Dunn, CJ | 1 |
| Willoughby, DA | 1 |
| Oppenheim, BE | 1 |
| Cantez, S | 1 |
| Forys, VA | 1 |
| Altman, RD | 1 |
| Brown, M | 1 |
| Gargano, F | 1 |
| Thomas, BJ | 1 |
| Amstutz, HC | 1 |
| Holzmann, H | 1 |
| Thiers, G | 1 |
| Altmeyer, P | 1 |
| Maul, FD | 1 |
| Hör, G | 1 |
| Bijvoet, OL | 1 |
| Nollen, AJ | 1 |
| Slooff, TJ | 1 |
| Feith, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis[NCT04303026] | Phase 3 | 70 participants (Anticipated) | Interventional | 2020-03-02 | Recruiting | ||
| Pilot, Open Non-controled Trial to Assess the Feasibility of Implementing Objective Parameters as Primary Endpoints in a Clinical Trial With Patients Affected by Knee Osteoarthritis[NCT03421054] | 8 participants (Actual) | Interventional | 2018-03-19 | Completed | |||
| Double Blind, Placebo Controlled Trial to Evaluate the Effects of a Nutraceutical Containing High-Molecular-Weight Hyaluronic Acid (HA) and Acetyl-11-Keto-Beta-Boswellic Acid (AKBA) in Patients Affected by Knee Osteoarthritis[NCT03612986] | 72 participants (Actual) | Interventional | 2018-08-22 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for etidronate and Arthritis, Degenerative
| Article | Year |
|---|---|
Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system.
Topics: Anthraquinones; Antirheumatic Agents; Calcitonin; Chondroitin Sulfates; Clinical Trials as Topic; Et | 2008 |
Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system.
Topics: Anthraquinones; Antirheumatic Agents; Calcitonin; Chondroitin Sulfates; Clinical Trials as Topic; Et | 2008 |
Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system.
Topics: Anthraquinones; Antirheumatic Agents; Calcitonin; Chondroitin Sulfates; Clinical Trials as Topic; Et | 2008 |
Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system.
Topics: Anthraquinones; Antirheumatic Agents; Calcitonin; Chondroitin Sulfates; Clinical Trials as Topic; Et | 2008 |
The futility of current approaches to chondroprotection.
Topics: Anti-Bacterial Agents; Bone Density Conservation Agents; Cartilage, Articular; Chondrocytes; Doxycyc | 2007 |
4 trials available for etidronate and Arthritis, Degenerative
| Article | Year |
|---|---|
Additive effects of glucosamine or risedronate for the treatment of osteoarthritis of the knee combined with home exercise: a prospective randomized 18-month trial.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; | 2008 |
Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.
Topics: Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Bone Density; Cohort Studies; Dose-Resp | 1994 |
Prevention of heterotopic bone formation: clinical experience with diphosphonates.
Topics: Clinical Trials as Topic; Etidronic Acid; Female; Follow-Up Studies; Hip Prosthesis; Humans; Male; M | 1987 |
[Therapy of psoriatic osteoarthropathy with EHDP].
Topics: Administration, Oral; Adult; Aged; Clinical Trials as Topic; Etidronic Acid; Female; Humans; Male; M | 1985 |
12 other studies available for etidronate and Arthritis, Degenerative
| Article | Year |
|---|---|
No effect of risedronate on articular cartilage damage in the Dunkin Hartley guinea pig model of osteoarthritis.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Calcification, Physiologic; Cartilage, A | 2013 |
Effects of glucosamine and risedronate alone or in combination in an experimental rabbit model of osteoarthritis.
Topics: Animals; Bone Density Conservation Agents; Etidronic Acid; Female; Glucosamine; Humans; Osteoarthrit | 2014 |
Risedronate-induced arthritis.
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Middle Aged; Osteoarthritis; Osteo | 2010 |
Antiresorptive therapy conserves some periarticular bone and ligament mechanical properties after anterior cruciate ligament disruption in the rabbit knee.
Topics: Animals; Anterior Cruciate Ligament; Biomechanical Phenomena; Bone Density; Etidronic Acid; Osteoart | 2004 |
Preservation of periarticular cancellous morphology and mechanical stiffness in post-traumatic experimental osteoarthritis by antiresorptive therapy.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Computer Simulation; Disease Models, Ani | 2008 |
Enzymatic release of microspheroids containing hydroxyapatite crystals from synovium and of calcium pyrophosphate dihydrate crystals from cartilage.
Topics: Calcium Pyrophosphate; Cartilage, Articular; Diphosphates; Etidronic Acid; Humans; Hydroxyapatites; | 1982 |
Identification of hydroxyapatite crystals in synovial fluid.
Topics: Adult; Aged; Arthritis, Juvenile; Arthritis, Rheumatoid; Chondrocalcinosis; Etidronic Acid; Female; | 1979 |
Potassium permanganate induced calcergy: a model to study the effects of drugs on hydroxyapatite crystal deposition.
Topics: Animals; Calcinosis; Clodronic Acid; Dexamethasone; Disease Models, Animal; Etidronic Acid; Hydroxya | 1979 |
What causes lower neck uptake in bone scans?
Topics: Adult; Cervical Vertebrae; Diphosphates; Etidronic Acid; Humans; Laryngeal Cartilages; Neoplasm Meta | 1977 |
Etidronate and osteoarthritis.
Topics: Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteoarthritis; Osteoporosis, Postmeno | 1991 |
Low back pain in Paget's disease of bone.
Topics: Back Pain; Diagnosis, Differential; Etidronic Acid; Humans; Osteitis Deformans; Osteoarthritis; Radi | 1987 |
Effect of a diphosphonate on para-articular ossification after total hip replacement.
Topics: Aged; Creatinine; Etidronic Acid; Female; Hip Joint; Humans; Male; Organophosphonates; Organophospho | 1974 |